Women-only HIV study improves understanding of effective, safe antiretroviral … – Vaccine News Daily
Vaccine News Daily |
Women-only HIV study improves understanding of effective, safe antiretroviral …
Vaccine News Daily The Women's Antiretroviral Efficacy and Safety Study (WAVES) was the first double-blind, randomized, antiretroviral (ARV) trial that involved only women. The purpose was to demonstrate the women using Stribild would have a statistically higher chance … |